![Xenon Pharmaceuticals Inc. logo](/logos/XENE.webp)
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
Overview | Financials
Company Name | Xenon Pharmaceuticals Inc. |
Symbol | XENE |
Currency | USD |
Price | 38.47 |
Market Cap | 2,914,660,315 |
Dividend Yield | 0% |
52-week-range | 27.985 - 50.99 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA |
Website | https://www.xenon-pharma.com |
An error occurred while fetching data.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD